These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 21182301)

  • 1. The W232R suppressor mutation promotes maturation of a truncation mutant lacking both nucleotide-binding domains and restores interdomain assembly and activity of P-glycoprotein processing mutants.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2011 Feb; 50(5):672-85. PubMed ID: 21182301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.
    Wang Y; Loo TW; Bartlett MC; Clarke DM
    Mol Pharmacol; 2007 Mar; 71(3):751-8. PubMed ID: 17132688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2005 Aug; 44(30):10250-8. PubMed ID: 16042402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
    Loo TW; Bartlett MC; Clarke DM
    Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of the P-glycoprotein first intracellular loop and flanking transmembrane domains.
    Kwan T; Gros P
    Biochemistry; 1998 Mar; 37(10):3337-50. PubMed ID: 9521654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insertion of an arginine residue into the transmembrane segments corrects protein misfolding.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2006 Oct; 281(40):29436-40. PubMed ID: 16926162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domain interdependence in the biosynthetic assembly of CFTR.
    Cui L; Aleksandrov L; Chang XB; Hou YX; He L; Hegedus T; Gentzsch M; Aleksandrov A; Balch WE; Riordan JR
    J Mol Biol; 2007 Jan; 365(4):981-94. PubMed ID: 17113596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Walker B motif of the second nucleotide-binding domain (NBD2) of CFTR plays a key role in ATPase activity by the NBD1-NBD2 heterodimer.
    Stratford FL; Ramjeesingh M; Cheung JC; Huan LJ; Bear CE
    Biochem J; 2007 Jan; 401(2):581-6. PubMed ID: 16989640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR).
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2008 Oct; 283(42):28190-7. PubMed ID: 18708637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginines in the first transmembrane segment promote maturation of a P-glycoprotein processing mutant by hydrogen bond interactions with tyrosines in transmembrane segment 11.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2008 Sep; 283(36):24860-70. PubMed ID: 18596043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2007 Nov; 282(44):32043-52. PubMed ID: 17848563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residues responsible for the asymmetric function of the nucleotide binding domains of multidrug resistance protein 1.
    Qin L; Zheng J; Grant CE; Jia Z; Cole SP; Deeley RG
    Biochemistry; 2008 Dec; 47(52):13952-65. PubMed ID: 19063607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
    Liu R; Sharom FJ
    Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?
    Loo TW; Clarke DM
    Biochem Biophys Res Commun; 2005 Apr; 329(2):419-22. PubMed ID: 15737603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2004 Sep; 43(38):12081-9. PubMed ID: 15379547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR.
    Loo TW; Clarke DM
    Biochem Pharmacol; 2017 Jul; 136():24-31. PubMed ID: 28366727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleotide binding domains of human CFTR: a structural classification of critical residues and disease-causing mutations.
    Eudes R; Lehn P; Férec C; Mornon JP; Callebaut I
    Cell Mol Life Sci; 2005 Sep; 62(18):2112-23. PubMed ID: 16132229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein: from genomics to mechanism.
    Ambudkar SV; Kimchi-Sarfaty C; Sauna ZE; Gottesman MM
    Oncogene; 2003 Oct; 22(47):7468-85. PubMed ID: 14576852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1).
    Ambudkar SV; Kim IW; Sauna ZE
    Eur J Pharm Sci; 2006 Apr; 27(5):392-400. PubMed ID: 16352426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.